摘要
目的:探讨重组人粒细胞集落刺激因子(rh-GCSF)在乳腺癌TAC化疗中的使用策略。方法:将2010年8月至2012年8月45例乳腺癌术后行TAC化疗的患者随机分三组,于化疗期间不同时期予不同剂量rh-GCSF。观察治疗后粒细胞变化情况。结果:对于重度骨髓抑制患者,200μg/d疗效优于100μg/d。300μg/d疗效同200μg/d。结论:因TAC化疗出现重度骨髓抑制的患者,建议在化疗后第5日至第10日行rh-GCSF连续注射,推荐剂量200μg/d。rh-GCSF使用的最佳方案,包括使用的时机、剂量、维持时间等,尚需在临床应用中摸索。
Objective：To approach the applying strategy of the recombinant granulo - eyte colony - stinmlating factor in women with breast cancer. Methods：All 45 women patients with breast canc, er receiving chemotherapy TAC were randomly divided into three groups with different - doses of rh - GCSF. And the changes of the granular cell wererecorded. Results：For women with severe myelosuppression, the effect of the group with 200μg/d was better than the group with 100μg/d and the same with the group with 300μg/d. Conclusion：Rh - GCSF with the dose of 200μg/d is suggested to administrated from the fifth day to the tenth day after the Chemo therapy. But the optimal applying strate- gy including the administration time, dose, time of therapy etc, should be approached in clinical application.
出处
《现代肿瘤医学》
CAS
2013年第12期2735-2738,共4页
Journal of Modern Oncology
